Pharmacogenomics Journal

Papers
(The median citation count of Pharmacogenomics Journal is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data49
Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs31
The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data29
Economic evaluation in psychiatric pharmacogenomics: a systematic review29
Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children’s Genomic Medicine Consortium23
A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy22
Pharmacogenomics cascade testing (PhaCT): a novel approach for preemptive pharmacogenomics testing to optimize medication therapy18
Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study17
Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle16
Does the RAAS play a role in loss of taste and smell during COVID-19 infections?15
Spectrum of cutaneous adverse reactions to aromatic antiepileptic drugs and human leukocyte antigen genotypes in Thai patients and meta-analysis15
Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan15
Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States14
Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection14
Pharmacogenetic information in Swiss drug labels – a systematic analysis13
Nine-gene pharmacogenomics profile service: The Mayo Clinic experience13
Global distribution of CYP2C19 risk phenotypes affecting safety and effectiveness of medications13
miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disorders12
Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population12
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel11
The variants at FLNA and FLNB contribute to the susceptibility of hypertension and stroke with differentially expressed mRNA10
Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review10
Genetic polymorphisms associated with upper gastrointestinal bleeding: a systematic review9
Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis9
G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-199
Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model9
Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore8
Association of HLA-DRB1*04:05 allele with drug-induced interstitial lung disease in Japanese population8
The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review8
Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis8
ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment8
Association of ITPA gene polymorphisms with adverse effects of AZA/6-MP administration: a systematic review and meta-analysis7
PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors7
CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice7
Pharmacogenetics in clinical practice: current level of knowledge among Flemish physicians and pharmacists7
The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals7
A systematic review on the cost effectiveness of pharmacogenomics in developing countries: implementation challenges7
The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer7
Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China6
Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes6
Oral absorption of voriconazole is affected by SLCO2B1 c.*396T>C genetic polymorphism in CYP2C19 poor metabolizers6
A review of the existing literature on buprenorphine pharmacogenomics6
Validated prognostic significance of YB-1 genetic variation in metastatic prostate cancer6
Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?6
The need of a multicomponent guiding approach to personalize clopidogrel treatment6
Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease5
ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy5
Influence of CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients5
HLA-B*07:02 and HLA-C*07:02 are associated with trimethoprim-sulfamethoxazole respiratory failure5
Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients5
Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder5
Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data5
Ischemic stroke and myocardial ischemia in clopidogrel users and the association with CYP2C19 loss-of-function homozygocity: a real-world study5
A blockchain-based framework to support pharmacogenetic data sharing5
Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care5
Genetic variants associated with cardiometabolic abnormalities during treatment with selective serotonin reuptake inhibitors: a genome-wide association study5
Bioinformatics driven discovery of small molecule compounds that modulate the FOXM1 and PPARA pathway activities in breast cancer4
Pharmacogenomic analysis of a genetically distinct Indigenous population4
Genome-wide association study of cardiovascular disease in testicular cancer patients treated with platinum-based chemotherapy4
Serotonergic receptor gene polymorphism and response to selective serotonin reuptake inhibitors in ethnic Malay patients with first episode of major depressive disorder4
Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder4
Transcriptional analysis of sodium valproate in a serotonergic cell line reveals gene regulation through both HDAC inhibition-dependent and independent mechanisms4
Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy4
Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis4
Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patients4
Using ChatGPT to predict the future of personalized medicine4
Rates of genetic testing in patients prescribed drugs with pharmacogenomic information in FDA-approved labeling4
Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women4
Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients4
New genetic variants associated with major adverse cardiovascular events in patients with acute coronary syndromes and treated with clopidogrel and aspirin4
The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens4
Implications of venous thromboembolism GWAS reported genetic makeup in the clinical outcome of ovarian cancer patients4
Knowledge and attitudes of medical and pharmacy students about pharmacogenomics: a systematic review and meta-analysis4
HLA-B*39:01:01 is a novel risk factor for antithyroid drug-induced agranulocytosis in Japanese population4
Group-based pharmacogenetic prediction: is it feasible and do current NHS England ethnic classifications provide appropriate data?3
Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population3
Predictive value of genetic variants XRCC1 rs1799782, APEX1 rs1760944, and MUTYH rs3219489 for adjuvant concurrent chemoradiotherapy outcomes in oral squamous cell carcinoma patients3
Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach3
Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers3
Identification of sex-specific genetic associations in response to opioid analgesics in a White, non-Hispanic cohort from Southeast Minnesota3
SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort3
Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder3
Pharmacoepigenomics circuits induced by a novel retinoid-polyamine conjugate in human immortalized keratinocytes3
A survey of cancer genome signatures identifies genes connected to distinct chromosomal instability phenotypes3
Overexpression of P-glycoprotein and MRP-1 are pharmacogenomic biomarkers to determine steroid resistant phenotype in childhood idiopathic nephrotic syndrome3
Genetic-guided pharmacotherapy for venous thromboembolism: a systematic and critical review of economic evaluations3
Population impact of pharmacogenetic tests in admixed populations across the Americas3
Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder3
Clinical utility of pharmacogenetics in a psychiatric and primary care population3
0.016968011856079